The landscape of metabolic brain alterations in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Introduction: Alzheimer's disease (AD) is accompanied by metabolic alterations both in the periphery and the central nervous system. However, so far, a global view of AD‐associated metabolic changes in the brain has been missing. Methods: We metabolically profiled 500 samples from the dorsolateral prefrontal cortex. Metabolite levels were correlated with eight clinical parameters, covering both late‐life cognitive performance and AD neuropathology measures. Results: We observed widespread metabolic dysregulation associated with AD, spanning 298 metabolites from various AD‐relevant pathways. These included alterations to bioenergetics, cholesterol metabolism, neuroinflammation, and metabolic consequences of neurotransmitter ratio imbalances. Our findings further suggest impaired osmoregulation as a potential pathomechanism in AD. Finally, inspecting the interplay of proteinopathies provided evidence that metabolic associations were largely driven by tau pathology rather than amyloid beta pathology. Discussion: This work provides a comprehensive reference map of metabolic brain changes in AD that lays the foundation for future mechanistic follow‐up studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
LOF: identifying density-based local outliers
Breunig, M. M., Kriegel, H.-P., Ng, R. T., & Sander, J. (2000) · ACM SIGMOD Record · doi:10.1145/335191.335388 · Cited by 5,207
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
LOF: identifying density-based local outliers
Breunig, M. M., Kriegel, H.-P., Ng, R. T., & Sander, J. (2000) · Proceedings of the 2000 ACM SIGMOD international conference on Management of data · doi:10.1145/342009.335388 · Cited by 4,149
Glutathione Metabolism and Its Implications for Health
Wu, G., Lupton, J. R., Turner, N. D., Fang, Y.-Z., & Yang, S. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.3.489 · Cited by 3,842 · cited 1×
“Significant metabolites included 4hydroxy-nonenal-glutathione, a marker for detoxification of lipid peroxidation through glutathione S-transferases (GSTs) (51); cysteinylglycine disulfide, a degradation product of oxidized glutathione (49); and ophthalmate, an endogenous analog of hepatic glutathione (GSH) and a poten…”
BackgroundProtein aggregation and neurodegenerative disease
Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454 · cited 2×
“(2) Establishing broad impairment of osmoregulation as a potentially relevant pathomechanism in AD.”
BackgroundNeuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179 · cited 1×
“Neuroinflammation is a central pathogenic feature of AD and is accompanied by the production of reactive oxygen species leading to oxidative stress (47).”
BackgroundTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Perineuronal nets stabilize the grid cell network
Christensen, A. C., Lensjø, K. K., Lepperød, M. E., Dragly, S.-A., Sutterud, H., Blackstad, J. S., Fyhn, M., & Hafting, T. (2021) · Nature Communications · doi:10.1038/s41467-020-20241-w · Cited by 1,865
Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: Recent advances.
Wang, W., Zhao, F., Ma, X., Perry, G., & Zhu, X. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00376-6 · Cited by 1,274
Alzheimer’s disease is type 3 diabetes—Evidence reviewed
de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158
Omega-3 Fatty Acids and Inflammatory Processes
Calder, P. C. (2010) · Nutrients · doi:10.3390/nu2030355 · Cited by 1,116
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049
Role of Glutamate and NMDA Receptors in Alzheimer’s Disease
Wang, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160763 · Cited by 1,009
Johnson, E. C. B., Dammer, E. B., Duong, D. M., Ping, L., Zhou, M., Yin, L., Higginbotham, L. A., Guajardo, A., White, B., Troncoso, J. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0815-6 · Cited by 1,001
Self-citationBlood-based biomarkers for Alzheimer disease: mapping the road to the clinic
Hampel, H., O’Bryant, S. E., Molinuevo, J. L., Zetterberg, H., Masters, C. L., Lista, S., Kiddle, S. J., Batrla, R., & Blennow, K. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0079-7 · Cited by 716
Mendelian randomization in cardiometabolic disease: challenges in evaluating causality
Holmes, M. V., Ala-Korpela, M., & Smith, G. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.78 · Cited by 679 · cited 1×
“causality analysis such as Mendelian randomization (93), for which our study did not have the necessary statistical power.”
BackgroundAmyloid-β-independent regulators of tau pathology in Alzheimer disease
van der Kant, R., Goldstein, L. S. B., & Ossenkoppele, R. (2020) · Nature reviews. Neuroscience · doi:10.1038/s41583-019-0240-3 · Cited by 580
Coon, K. D., Myers, A. J., Craig, D. W., Webster, J. A., Pearson, J. V., Lince, D. H., Zismann, V. L., Beach, T. G., Leung, D., Bryden, L., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0419 · Cited by 569
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
for the SCarlet RoAD Investigators, Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0318-y · Cited by 567
Randomized trial of verubecestat for prodromal Alzheimer's disease
Egan, M. F., Kost, J., Voss, T., Mukai, Y., Aisen, P. S., Cummings, J. L., Tariot, P. N., Vellas, B., van Dyck, C. H., Boada, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812840 · Cited by 545
Yurdagul, A., Subramanian, M., Wang, X., Crown, S. B., Ilkayeva, O. R., Darville, L., Kolluru, G. K., Rymond, C. C., Gerlach, B. D., Zheng, Z., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.01.001 · Cited by 525 · cited 1×
“Putrescine promotes the clearance of apoptotic cells via efferocytosis (70), a mechanism affected in AD and other neurodegenerative diseases (71).”
BackgroundSelf-citationMostafavi, S., Gaiteri, C., Sullivan, S. E., White, C. C., Tasaki, S., Xu, J., Taga, M., Klein, H.-U., Patrick, E., Komashko, V., et al. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0154-9 · Cited by 509 · cited 1×
“All clinical parameters have previously been described in detail (13).”
BackgroundSelf-citationAllen, M., Carrasquillo, M. M., Funk, C., Heavner, B. D., Zou, F., Younkin, C. S., Burgess, J. D., Chai, H.-S., Crook, J., Eddy, J. A., et al. (2016) · Scientific Data · doi:10.1038/sdata.2016.89 · Cited by 439 · cited 1×
“Details on this cohort have been provided in previous studies (18,19).”
MethodSelf-citationAPOE and Alzheimer’s Disease: From Lipid Transport to Physiopathology and Therapeutics
Husain, M. A., Laurent, B., & Plourde, M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.630502 · Cited by 353
Nho, K., Kueider‐Paisley, A., MahmoudianDehkordi, S., Arnold, M., Risacher, S. L., Louie, G., Blach, C., Baillie, R., Han, X., Kastenmüller, G., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.012 · Cited by 343
Self-citationBi, D., Wen, L., Wu, Z., & Shen, Y. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12088 · Cited by 232
Sex and APOE ε4 genotype modify the Alzheimer’s disease serum metabolome
Arnold, M., Nho, K., Kueider-Paisley, A., Massaro, T., Huynh, K., Brauner, B., MahmoudianDehkordi, S., Louie, G., Moseley, M. A., Thompson, J. W., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14959-w · Cited by 202
Self-citationKrumsiek, J., Suhre, K., Evans, A. M., Mitchell, M. W., Mohney, R. P., Milburn, M. V., Wägele, B., Römisch-Margl, W., Illig, T., Adamski, J., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1003005 · Cited by 197
Self-citationPreliminary Results of a Trial of Atabecestat in Preclinical Alzheimer’s Disease
Henley, D., Raghavan, N., Sperling, R., Aisen, P., Raman, R., & Romano, G. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1813435 · Cited by 197
Conserved brain myelination networks are altered in Alzheimer’s and other neurodegenerative diseases
Allen, M., Wang, X., Burgess, J. D., Watzlawik, J., Serie, D. J., Younkin, C. S., Nguyen, T., Malphrus, K. G., Lincoln, S., Carrasquillo, M. M., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.09.012 · Cited by 143 · cited 1×
“Details on this cohort have been provided in previous studies (18,19).”
MethodSelf-citationLate-onset Alzheimer’s disease is associated with inherent changes in bioenergetics profiles
Sonntag, K.-C., Ryu, W.-I., Amirault, K. M., Healy, R. A., Siegel, A. J., McPhie, D. L., Forester, B., & Cohen, B. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-14420-x · Cited by 131
McKay, G. J., Silvestri, G., Chakravarthy, U., Dasari, S., Fritsche, L. G., Weber, B. H., Keilhauer, C. N., Klein, M. L., Francis, P. J., Klaver, C. C., et al. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwr015 · Cited by 105
Ma, C., Hunt, J. B., Selenica, M.-L. B., Sanneh, A., Sandusky-Beltran, L. A., Watler, M., Daas, R., Kovalenko, A., Liang, H., Placides, D., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.582998 · Cited by 24
Cited by
Brain high-throughput multi-omics data reveal molecular heterogeneity in Alzheimer’s disease
Eteleeb, A. M., Novotny, B. C., Tarraga, C. S., Sohn, C., Dhungel, E., Brase, L., Nallapu, A., Buss, J., Farias, F., Bergmann, K., et al. (2024) · PLOS Biology · doi:10.1371/journal.pbio.3002607 · Cited by 64
Reddy, J. S., Heath, L., Linden, A. V., Allen, M., Lopes, K. D. P., Seifar, F., Wang, E., Ma, Y., Poehlman, W. L., Quicksall, Z. S., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14208 · Cited by 29
Self-citationBorkowski, K., Liang, N., Zhao, N., Arnold, M., Huynh, K., Karu, N., Mahmoudiandehkordi, S., Kueider-Paisley, A., Kanekiyo, T., Bu, G., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00888-z · Cited by 7
Self-citation
Metadata
- Authors
- Batra, R., Arnold, M., Wörheide, M. A., Allen, M., Wang, X., Blach, C., Levey, A. I., Seyfried, N. T., Ertekin‐Taner, N., Bennett, D. A., Kastenmüller, G., Kaddurah‐Daouk, R. F., Krumsiek, J., & for the Alzheimer's Disease Metabolomics Consortium (ADMC)
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2022-07-13
- Volume
- 19
- Issue
- 3
- Pages
- 980-998
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W4285394036
- Cited by
- 93
- References
- 34
- FWCI
- 7.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.